Business Description
Propanc Biopharma is an Australian biotech company focused on developing new treatments for pancreatic, ovarian, and colorectal cancers. Its main drug candidate, PRP, is an intravenous therapy that uses proenzymes to target and prevent cancer, and has already completed pre-clinical testing. The company works alongside the Universities of Jaén and Granada to advance its research programs and develop an improved synthetic form of PRP. Founded in 2007 and headquartered in Camberwell, Australia, Propanc Biopharma continues to build on its pipeline of cancer therapies.
